 Gemlyn George
Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombocytopenia | 4 | 2022 | 177 | 1.180 |
Why?
| | Graft vs Host Disease | 4 | 2020 | 212 | 1.050 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2020 | 520 | 0.970 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 21 | 0.740 |
Why?
| | Asparaginase | 1 | 2020 | 31 | 0.700 |
Why?
| | Antithrombins | 1 | 2020 | 49 | 0.690 |
Why?
| | Venous Thrombosis | 1 | 2020 | 140 | 0.620 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2021 | 858 | 0.600 |
Why?
| | Carcinoma, Renal Cell | 1 | 2020 | 168 | 0.590 |
Why?
| | Proteinuria | 1 | 2017 | 77 | 0.570 |
Why?
| | Thrombelastography | 1 | 2018 | 180 | 0.560 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 256 | 0.560 |
Why?
| | Liver Cirrhosis | 1 | 2018 | 227 | 0.540 |
Why?
| | Kidney Neoplasms | 1 | 2020 | 327 | 0.510 |
Why?
| | Polyethylene Glycols | 1 | 2020 | 561 | 0.500 |
Why?
| | Multiple Myeloma | 3 | 2023 | 93 | 0.480 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2017 | 401 | 0.450 |
Why?
| | Vaccination | 1 | 2021 | 1204 | 0.430 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 2 | 2022 | 12 | 0.410 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1355 | 0.400 |
Why?
| | Hematologic Neoplasms | 2 | 2023 | 137 | 0.360 |
Why?
| | Anemia, Sickle Cell | 2 | 2023 | 215 | 0.340 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2020 | 56 | 0.330 |
Why?
| | Stroke | 1 | 2017 | 1021 | 0.320 |
Why?
| | Platelet Factor 4 | 3 | 2022 | 21 | 0.310 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 231 | 0.300 |
Why?
| | beta-Thalassemia | 1 | 2023 | 23 | 0.220 |
Why?
| | Retrospective Studies | 9 | 2021 | 12545 | 0.210 |
Why?
| | Humans | 25 | 2023 | 114655 | 0.210 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 92 | 0.200 |
Why?
| | Middle Aged | 8 | 2020 | 26733 | 0.200 |
Why?
| | Upper Extremity Deep Vein Thrombosis | 1 | 2021 | 2 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 83 | 0.190 |
Why?
| | Central Venous Catheters | 1 | 2021 | 40 | 0.180 |
Why?
| | Adult | 9 | 2023 | 30543 | 0.180 |
Why?
| | Antibodies | 1 | 2022 | 371 | 0.180 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2020 | 71 | 0.180 |
Why?
| | Vaccines | 2 | 2022 | 375 | 0.170 |
Why?
| | Lymphoma, Follicular | 1 | 2020 | 35 | 0.170 |
Why?
| | Primary Myelofibrosis | 1 | 2020 | 9 | 0.170 |
Why?
| | Retreatment | 1 | 2020 | 67 | 0.170 |
Why?
| | Ipilimumab | 1 | 2020 | 27 | 0.170 |
Why?
| | Pyrimidines | 2 | 2020 | 376 | 0.170 |
Why?
| | Cryoglobulinemia | 1 | 2019 | 5 | 0.170 |
Why?
| | Pyrazoles | 2 | 2020 | 362 | 0.170 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 181 | 0.160 |
Why?
| | Withholding Treatment | 1 | 2019 | 68 | 0.160 |
Why?
| | Transplantation, Homologous | 1 | 2020 | 377 | 0.160 |
Why?
| | Salvage Therapy | 1 | 2020 | 127 | 0.160 |
Why?
| | Vasculitis | 1 | 2019 | 66 | 0.160 |
Why?
| | Recurrence | 2 | 2021 | 935 | 0.160 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 95 | 0.150 |
Why?
| | Hodgkin Disease | 1 | 2020 | 121 | 0.150 |
Why?
| | Blood Platelets | 2 | 2022 | 351 | 0.150 |
Why?
| | Aged | 7 | 2020 | 19069 | 0.150 |
Why?
| | Thrombosis | 1 | 2021 | 298 | 0.150 |
Why?
| | Male | 10 | 2020 | 55580 | 0.150 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 234 | 0.130 |
Why?
| | Length of Stay | 1 | 2020 | 962 | 0.130 |
Why?
| | Hospitals | 1 | 2020 | 581 | 0.130 |
Why?
| | Lymphocytes | 1 | 2016 | 330 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2017 | 299 | 0.110 |
Why?
| | Patient-Centered Care | 1 | 2019 | 473 | 0.110 |
Why?
| | Anticoagulants | 3 | 2022 | 550 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 785 | 0.110 |
Why?
| | Female | 8 | 2020 | 59489 | 0.100 |
Why?
| | Celiac Disease | 1 | 2016 | 264 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1796 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2018 | 707 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2023 | 176 | 0.090 |
Why?
| | Heparin | 2 | 2022 | 224 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2018 | 2762 | 0.090 |
Why?
| | India | 3 | 2019 | 134 | 0.090 |
Why?
| | Neutrophils | 1 | 2016 | 1176 | 0.090 |
Why?
| | Adolescent | 5 | 2020 | 17838 | 0.090 |
Why?
| | Porphyromonas | 1 | 2009 | 1 | 0.090 |
Why?
| | Eubacterium | 1 | 2009 | 3 | 0.090 |
Why?
| | Bifidobacterium | 1 | 2009 | 21 | 0.080 |
Why?
| | Bacteroides | 1 | 2009 | 16 | 0.080 |
Why?
| | Cohort Studies | 1 | 2017 | 4895 | 0.070 |
Why?
| | Intestines | 1 | 2009 | 326 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2020 | 9088 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1078 | 0.060 |
Why?
| | Melphalan | 1 | 2023 | 29 | 0.050 |
Why?
| | Obesity | 2 | 2019 | 2508 | 0.050 |
Why?
| | Cryopreservation | 1 | 2022 | 92 | 0.050 |
Why?
| | Thrombin | 1 | 2023 | 139 | 0.050 |
Why?
| | Prevalence | 2 | 2019 | 2250 | 0.050 |
Why?
| | Catheters | 1 | 2021 | 63 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 493 | 0.050 |
Why?
| | Monocytes | 1 | 2023 | 502 | 0.040 |
Why?
| | Upper Extremity | 1 | 2021 | 84 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 797 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1080 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 220 | 0.040 |
Why?
| | Busulfan | 1 | 2020 | 14 | 0.040 |
Why?
| | Vidarabine | 1 | 2020 | 26 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 40 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 3327 | 0.040 |
Why?
| | Plasmapheresis | 1 | 2019 | 22 | 0.040 |
Why?
| | Prednisolone | 1 | 2019 | 75 | 0.040 |
Why?
| | Nitriles | 1 | 2020 | 149 | 0.040 |
Why?
| | Lipids | 1 | 2023 | 580 | 0.040 |
Why?
| | Transplantation Conditioning | 1 | 2020 | 151 | 0.040 |
Why?
| | Young Adult | 3 | 2019 | 10466 | 0.040 |
Why?
| | Rituximab | 1 | 2019 | 150 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 233 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 770 | 0.040 |
Why?
| | Piperidines | 1 | 2019 | 160 | 0.040 |
Why?
| | Milk | 1 | 2019 | 124 | 0.040 |
Why?
| | Adenine | 1 | 2019 | 219 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 836 | 0.040 |
Why?
| | Body Mass Index | 2 | 2019 | 1958 | 0.040 |
Why?
| | Proteins | 1 | 2023 | 908 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1211 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6345 | 0.030 |
Why?
| | Macrophages | 1 | 2023 | 1261 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2380 | 0.030 |
Why?
| | Antinematodal Agents | 1 | 2016 | 5 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 397 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1262 | 0.030 |
Why?
| | Edible Grain | 1 | 2016 | 43 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 385 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 442 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 1840 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 1715 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2016 | 604 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2478 | 0.030 |
Why?
| | Age Factors | 1 | 2019 | 2894 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6217 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4411 | 0.020 |
Why?
| | Animals | 2 | 2023 | 31698 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2009 | 79 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2009 | 218 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2009 | 138 | 0.020 |
Why?
| | Child | 2 | 2023 | 18407 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 311 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 8631 | 0.020 |
Why?
| | Mice | 1 | 2023 | 14863 | 0.020 |
Why?
| | United States | 1 | 2023 | 12180 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 427 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1879 | 0.020 |
Why?
|
|
George's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|